



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service  
National Institutes of Health

Office of Technology Transfer  
National Institutes of Health  
6011 Executive Boulevard  
Rockville, MD 20852

November 9, 2012

Krista L. Cox  
Knowledge Ecology International  
1621 Connecticut Avenue, Suite 500  
Washington, DC 20009

Dear Ms. Cox:

This is to acknowledge receipt of your letter dated October 25, 2012 on behalf of the American Medical Students Association, Knowledge Ecology International, U.S. Public Interest Group and the Universities Allied for Essential Medicines to the National Institutes of Health (NIH) Director, Dr. Francis S. Collins.

Consideration of your request for NIH to exercise its march-in rights for the patents held by Abbott Laboratories for the manufacture and sale of ritonavir has been delegated to NIH's Office of Technology Transfer (OTT). Consistent with 37 C.F.R. 401.6 (b), NIH has begun to review the issues you have brought to our attention.

You may contact me or Ann M. Hammersla, Director, Division of Policy, OTT at [hammerslaa@od.nih.gov](mailto:hammerslaa@od.nih.gov) or 301-435-5294 if you have further questions. We expect to respond to your request before the end of the year.

Sincerely,

A handwritten signature in blue ink, appearing to read "Mark L. Rohrbaugh", is written over a large, stylized blue flourish that extends to the right.

Mark L. Rohrbaugh, Ph.D., J.D.  
Director, Office of Technology Transfer

cc: Ann M. Hammersla, J.D.

MLR:sf